Ultragenyx Pharmaceutical Inc (FRA:UP0)
€ 46 -0.2 (-0.43%) Market Cap: 4.37 Bil Enterprise Value: 3.82 Bil PE Ratio: 0 PB Ratio: 13.49 GF Score: 79/100

Ultragenyx Pharmaceutical Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 12, 2019 / 06:30PM GMT
Release Date Price: €33.6 (-2.89%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Okay. Everybody, hey, I'm Marty Auster. I'm the smid cap -- lead smid cap biotech analyst at Crédit Suisse. Welcome to the prelunch session. We've got Ultragenyx Pharmaceuticals here and CEO, Emil Kakkis.

Questions & Answers

Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

I think few things we're going to want to talk about today, the commercial business, which has been growing steadily in 2019 and focus on the pipeline as well in gene therapy as well most new modalities you're working around, but maybe I can hand it to you for an intro and maybe kind of putting 2019 in a capsule and...

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Well, I think, 2019 has been a transformative year, but our stock price is not reflecting that. I think maybe everyone is out buying stock today. I don't know. Maybe. Hopefully. The

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot